Public-registry site landscape for NCT07679893, “Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis”, a Idiopathic Pulmonary Fibrosis study sponsored by Mannkind Corporation. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07679893 (registry record) |
| Study title | Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial of the Efficacy and Safety of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis Followed by an Open-Label Extension |
| Sponsor | Mannkind Corporation |
| Condition(s) | Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF) |
| Phase | PHASE2 |
| Listed sites | 1 |
| Intervention(s) | Nintedanib Dry Powder Inhalation, Placebo |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT07679893.
Eichor generates a preliminary site-risk snapshot for NCT07679893 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
